[3]Kosiborod Mikhail N et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial[J]. Circulation, 2020, 141(2): 90-99. [4]Martinez ...
Four large-scale trials in type 2 diabetes have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent the occurrence of serious heart failure events. Additionally, the DAPA-HF trial demonstrated a benefit of da...
[2] John J.V.McMurray,David L.DeMets,Silvio E.Inzucchi,etc.A trial to evaluate the effect of the sodium–glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)[J].European Journal of H...
3月31日,JAMA子刊——JAMA Cardiology在线发表了DAPA-HF研究(the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial)的新进展。 本次发布的研究结果旨在探索与安慰剂相比,SGLT-2抑制剂达格列净应用于射血分数降低的心衰(HFrEF)患者的疗效和安全性。 研究简介 该研究是一项在全球20个国家、...
4) a decline in eGFR of ≥50%; (5) a decline in eGFR of ≥40%; and (6) participant-level eGFR slope. For this outcome, the win ratio was 1.10 (95% confidence interval (CI) = 1.06-1.15) in the combined dataset, 1.08 (95% CI = 1.01-1.16) in the DAPA-HF trial ...
The DAPA-HF trial evaluated the safety and efficacy of dapagliflozin in patients with HF with reduced ejection fraction regardless of the presence of diabetes. It was an international, multi-center, randomized, placebo-controlled study, with blinding of patients and all study personnel, a low ...
1. McMurray JJV, DeMets DL, Inzucchi SE, et al. A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). European Journal of Heart Failure....
In theDAPA-HFtrial, treatment with the SGLT2 inhibitordapagliflozin(Farxiga, AstraZeneca) on top of standard HFrEF meds, compared with standard meds only, led to significantly improved risknot onlyfor its clinical composite primary endpoint, but for mortality and a slew of other meaningful secondary...
In a randomized trial of patients with heart failure and reduced ejection fraction, the SGLT2 inhibitor dapagliflozin markedly reduced mortality and worsening heart failure (McMurray et al., 2019). Remarkably, these benefits seemed to be similar in people with and without diabetes. These data usher...
科室小讲座 DAPAHF解读(1)钠-葡萄糖共转运体-2抑制剂(SGLT-2i)在心力衰竭中的治疗进展 历时20多年，糖尿病管理指南迭代更新逐步走向以心血管结局为中心T2DM管理时代 风险预防探讨心血管安全性存疑 1990 2000 20072008 CV事件不尽人意 2009 2010 2015 2016 新的曙光 2017201820192020 DCCTUKPDS控制血糖可减少糖尿 病...